Effect of Multidrug-Resistant-proteins in Neoadjuvant Chemotherapy in Patients with Breast Cancer
LIU Zhenzhen,LIU Hui,Li Lianfang,Cui Shude
DOI: https://doi.org/10.3969/j.issn.1671-6825.2005.05.020
2005-01-01
Abstract:Aim: To determine the expressions of P-glycoprotein(P-gp),glutathione S-transferase Pi(GST-π),and topoisomerase Ⅱ(TopoⅡ) in patients with breast cancer,and evaluate their predictive value in neoadjuvant chemotherapy. Methods: The expressions of P-gP,GST-π,and TopoⅡ were determined in 100 patients with breast cancer before and after neoadjuvant chemotherapy. Results:The positive expression rate of P-gp was 42% and 65% before and after chemotherapy,respectively,and the difference was statistically significant(P0.05 ).The positive expression rate of GST-π was 65% and 70%,and those of TopoⅡ was 40% and 35% before and after chemotherapy, respectively,and there was no significant differences in both GST-π and TopoⅡ positive expression rate before and after chemotherapy(P0.05).P-gp and GST-π positive expressions were positively correlated before chemotherapy(r=0.539,P0.01).In patients with P-gp,GST-π,and TopoⅡ positive expression,the response rates towards chemotherapy were 28.6%,46.2%,and 75.0%,and in patients without P-gp,GST-π,and TopoⅡ positive expression,the response rates were 55.0%(P0.05),60.0%(P0.05),and 35.0%(P0.05),respectively.The response rate of patients with both P-gp and GST-π expression was 25%.Conclusion:P-gp and TopoⅡ can be used to predict the therapeutic effect of neoadjuvant chemotherapy.